Validus Cellular Therapeutics
Treating Untreatable Infections
Treating Untreatable Infections
Validus Cellular Therapeutics is a renowned player in the Health Care industry, offering a groundbreaking solution for chronic resistant infections with its flagship product VCT-101. Unlike traditional antibiotics, VCT-101 boasts a novel preclinical anti-infective therapy that targets infections with a distinct mechanism, reducing susceptibility to resistance. This innovative cell therapy, aimed at bolstering the immune system and facilitating direct bacterial killing, holds promise in treating previously untreatable infections. Founded in 2016 and headquartered in the United States, the company recently secured a $20.20K Debt Financing investment on 11 August 2020. With its revolutionary approach to combating chronic infections, Validus Cellular Therapeutics is poised to make a significant impact in the healthcare landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $20.20K | - | 11 Aug 2020 |
No recent news or press coverage available for Validus Cellular Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
